Reasons for exclusion from thrombolytic therapy following acute ischemic stroke

被引：121

作者：

Cocho, D

Belvís, R

Martí-Fàbregas, J

Molina-Porcel, L

Díaz-Manera, J

Aleu, A

Pagonabarraga, J

García-Bargo, D

Mauri, A

Martí-Vilalta, JL

机构：

[1] Univ Autonoma Barcelona, Serv Neurol, Hosp Santa Cruz & San Pablo, Dept Neurol,Cerebrovasc Unit, E-08025 Barcelona, Spain

[2] Univ Autonoma Barcelona, Dept Emergency, Hosp Santa Cruz & San Pablo, E-08025 Barcelona, Spain

来源：

NEUROLOGY | 2005年 / 64卷 / 04期

关键词：

D O I：

10.1212/01.WNL.0000152041.20486.2F

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Despite evidence for the efficacy of thrombolytic therapy in acute ischemic stroke, only 1 to 7% of patients receive this therapy. The authors sought to determine the reasons for exclusion from tissue plasminogen activator (tPA) in an acute setting and found avoidable causes in 18% of patients. Improvements in intrahospital coordination would increase the number of patients who might benefit from tPA treatment at the authors' center.

引用

页码：719 / 720

页数：2

共 9 条

[1] Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility
Barber, PA
Zhang, J
Demchuk, AM
Hill, MD
Buchan, AM
[J]. NEUROLOGY, 2001, 56 (08) : 1015 - 1020
[2] Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)
Hacke, W
Kaste, M
Fieschi, C
von Kummer, R
Davalos, A
Meier, D
Larrue, V
Bluhmki, E
Davis, S
Donnan, G
Schneider, D
Diez-Tejedor, E
Trouillas, P
[J]. LANCET, 1998, 352 (9136) : 1245 - 1251
[3] Use of tissue-type plasminogen activator for acute ischemic stroke - The Cleveland area experience
Katzan, IL
Furlan, AJ
Lloyd, LE
Frank, JI
Harper, DL
Hinchey, JA
Hammel, JP
Qu, A
Sila, CA
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (09): : 1151 - 1158
[4] Intravenous tPA for ischemic stroke team performance over time, safety, and efficacy in a single-center, 2-year experience
Koennecke, HC
Nohr, R
Leistner, S
Marx, P
[J]. STROKE, 2001, 32 (05) : 1074 - 1078
[5] TISSUE-PLASMINOGEN ACTIVATOR FOR ACUTE ISCHEMIC STROKE
MARLER, JR
BROTT, T
BRODERICK, J
KOTHARI, R
ODONOGHUE, M
BARSAN, W
TOMSICK, T
SPILKER, J
MILLER, R
SAUERBECK, L
JARRELL, J
KELLY, J
PERKINS, T
MCDONALD, T
RORICK, M
HICKEY, C
ARMITAGE, J
PERRY, C
THALINGER, K
RHUDE, R
SCHILL, J
BECKER, PS
HEATH, RS
ADAMS, D
REED, R
KLEI, M
HUGHES, S
ANTHONY, J
BAUDENDISTEL, D
ZADICOFF, C
RYMER, M
BETTINGER, I
LAUBINGER, P
SCHMERLER, M
MEIROSE, G
LYDEN, P
RAPP, K
BABCOCK, T
DAUM, P
PERSONA, D
BRODY, M
JACKSON, C
LEWIS, S
LISS, J
MAHDAVI, Z
ROTHROCK, J
TOM, T
ZWEIFLER, R
DUNFORD, J
ZIVIN, J
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (24) : 1581 - 1587
[6] Thrombolytic therapy for acute ischemic stroke: Why the majority of patients remain ineligible for treatment
O'Connor, RE
McGraw, P
Edelsohn, L
[J]. ANNALS OF EMERGENCY MEDICINE, 1999, 33 (01) : 9 - 14
[7] Rey A, 1995, Rev Neurol, V23, P272
[8] Delayed hospital arrival for acute stroke: The Minnesota stroke survey
Smith, MA
Doliszny, KM
Shahar, E
McGovern, PG
Arnett, DK
Luepker, RV
[J]. ANNALS OF INTERNAL MEDICINE, 1998, 129 (03) : 190 - +
[9] Systematic review of evidence on thrombolytic therapy for acute ischaemic stroke
Wardlaw, JM
Warlow, CP
Counsell, C
[J]. LANCET, 1997, 350 (9078) : 607 - 614

← 1 →